Actively Recruiting
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Led by Regeneron Pharmaceuticals · Updated on 2026-05-08
915
Participants Needed
16
Research Sites
454 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard treatments for progressive Multiple Myeloma (MM) after at least 1 but no more than 3 prior therapies. The aim of this study is to see if the safety and efficacy of linvoseltamab alone or in combination with carfilzomib can deliver better outcomes (deeper and longer responses that help extend life) than standard treatment options. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
CONDITIONS
Official Title
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult participants with relapsed or refractory Multiple Myeloma who have had at least 1 but no more than 3 prior treatments
- Prior therapies must have included lenalidomide and either a Protease Inhibitor or an anti-CD38 monoclonal antibody
- Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less
- Confirmed disease progression during or after the most recent therapy according to IMWG criteria
You will not qualify if you...
- Prior treatment with T cell-based immunotherapy targeting BCMA, including BCMA-directed bispecific antibodies, Bispecific T-cell Engagers (BiTEs), or Chimeric Antigen Receptor (CAR) T cells
- Diagnosis of plasma cell leukemia, symptomatic amyloidosis (including myeloma-associated amyloidosis), Waldenström macroglobulinemia, or POEMS syndrome
- Known Central Nervous System involvement of myeloma, including meningeal involvement
- History of neurodegenerative conditions, Progressive Multifocal Leukoencephalopathy (PML), or central nervous system movement disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 16 locations
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021
Actively Recruiting
2
OhioHealth
Columbus, Ohio, United States, 43214
Actively Recruiting
3
Mater Misericordiae Ltd
Brisbane, Queensland, Australia, 4101
Actively Recruiting
4
Gold Coast Hospital and Health Service
Southport, Queensland, Australia, 4215
Actively Recruiting
5
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea, 58128
Actively Recruiting
6
Seoul National University Hospital
Seoul, South Korea, 03080
Actively Recruiting
7
Severance Hospital; Division of Hematology
Seoul, South Korea, 03722
Actively Recruiting
8
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
9
Seoul St. Mary's Hospital, The Catholic University of Korea
Seoul, South Korea, 06591
Actively Recruiting
10
Ulsan University Hospital
Ulsan, South Korea, 44033
Actively Recruiting
11
Aberdeen Royal Infirmary
Aberdeen, Aberdeenshire, United Kingdom, AB25 2ZN
Actively Recruiting
12
Royal Cornwall Hospital National Health Service (NHS) Foundation Trust
Truro, Cornwall, United Kingdom, TR1 3LJ
Actively Recruiting
13
University Hospitals Plymouth National Health Service (NHS) Foundation Trust - Hematology
Plymouth, Devon, United Kingdom, PL6 8DH
Actively Recruiting
14
Norfolk and Norwich University Hospital National Health Service (NHS) Foundation Trust
Norwich, Norfolk, United Kingdom, NR4 7UY
Actively Recruiting
15
University Hospitals Birmingham NHS Trust, Center for Clinical
Birmingham, West Midlands, United Kingdom, B15 2GW
Actively Recruiting
16
Ninewells Hospital and Medical School
Dundee, United Kingdom, DD1 9SY
Actively Recruiting
Research Team
C
Clinical Trials Administrator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here